It is widely accepted that protein oxidation is involved in a variety of diseases, including neurodegenerative diseases. Especially during aging, a reduction in anti-oxidant defence mechanisms leads to an increased formation of free radical oxygen species and consequently results in a damage of proteins, including mitochondrial and synaptic ones. Even those proteins involved in repair and protein clearance via the ubiquitin proteasome and lysosomal system are subject to damage and show a reduced function. Here, we will discuss a variety of mechanisms and provide examples where cognition is affected and where repair mechanisms are no longer sufficient to compensate for a dysfunction of damaged proteins or even may become toxic. Next to physiological deficits, an accumulation of deficient proteins in aggresomes may occur and result in a formation of pathological hallmark structures typical for aging and disease. A major challenge is how to prevent aberrant oxidation, given that oxidation plays an essential role in aging and neurodegenerative diseases. Particularly interesting are the possibilities to reduce the formation of radical oxygen species leading to a dysfunction of protein repair and protein clearance, or to a formation of toxic byproducts accelerating neurodegeneration.
StadtmanER. Protein oxidation and aging. Free Rad Res2006; 40: 1250–8.
2.
RiedererBMLeubaGVernayARiedererIM. The role of the ubiquitin proteasome system in Alzheimer's disease. Exp Biol Med2011; 236: 268–76.
3.
GuptaSCKimJHKannappanRReuterSDoughertyPMAggarwalBB. Role of nuclear factor kappaB-mediated inflammatory pathways in cancer-related symptoms and their regulation by nutritional agents. Exp Biol Med2011; 236: 658–71.
4.
IharaYMorishima-KawashimaMNixonR. The ubiquitin-proteasome system and the autophagic-lysosomal system in Alzheimer disease. CSH Persp Med2012; 2: a006361–a006361.
5.
MurphyMP. How mitochondria produce reactive oxygen species. Biochem J2009; 417: 1–13.
6.
MasliahEMalloryMHansenLDeTeresaRTerryRD. Quantitative synaptic alterations in the human neocortex during normal aging. Neurology1993; 43: 192–7.
7.
AndertonBH. Ageing of the brain. Mech Ageing Devel2002; 123: 811–17.
8.
ReddyPHManiGParkBS. Differential loss of synaptic proteins in Alzheimer's disease: implications for synaptic dysfunction. J Alz Dis2005; 7: 103–17.
9.
BaloyannisSJ. Mitochondria are related to synaptic pathology in Alzheimer's disease. Int J Alz Dis2011; 2011: 1–7.
ReddyPHTripathiRTroungQTirumalaKReddyTPAnekondaVShirendebUPCalkinsMJReddyAPMaoPManczakM. Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: implications to mitochondria-targeted antioxidant therapeutics. Biochim Biophys Acta2012; 1822: 639–49.
12.
Lasagna-ReevesCACastillo-CarranzaDLSenguptaUClosALJacksonGRKayedR. Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. Mol Neurodeg2011; 6: 1–14.
13.
HooverBRReedMNSuJPenrodRDKotilinekLAGrantMKPitstickRPCarlsonGALanierLMYuanL-LAsheKHLiaoD. Tau mislocalzation to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron2010; 68: 1067–81.
14.
MinS-WChoS-HZhouYSchroederSHaroutiunianVSeeleyWWHuangEJShenYMasliahEMukherjeeCMeyersDColePAOttMGanL. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron2010; 67: 953–66.
15.
MandelkowE-MMandelkowE. Biochemistry and cell biology of tau protein in neurofibrillary degeneration. CSH Perspect Med2012; 2: a006247–a006247.
16.
RobersonEDHalabiskyBYooJWYaoJChinJYanFWuTHamtoPDevidzeNYuG-QPalopJJNoebelsJLMuckeL. Amyloid-ß/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J Neurosci2011; 31: 700–11.
17.
LiptonSAChoiY-BTakahashiHZhangDLiWGodzikABankstonLA. Cysteine regulation of protein function – as exemplified by NMDA-receptor modulation. Trends Neurosci2002; 25: 474–80.
18.
NakamuraTLiptonSA. Redox modulation by S-nitrosylation contributes to protein misfolding, mitochondrial dynamics, and neuronal synaptic damage in neurodegenerative diseases. Cell Death Differ2011; 18: 1478–86.
19.
von BernhardiREugeninJ. Alzheimer's disease: redox dysregulation as a common denominator for diverse pathogenic mechanisms. Antioxid Redox Signal2012; 16: 974–1031.
20.
LeeCYuM-H. Protein folding and disease. J Biochem Mol Biol2005; 38: 275–80.
21.
ZouambiaMFischerDFHoboBDe VosRAHolEMVarndellIMSheppardPWVan LeeuwenFW. Proteasome subunit proteins and neuropathology in tauopathies and synucleinopathies: consequences for proteomic analyses. Proteomics2008; 8: 1221–36.
22.
ButterfieldDAPerluigiMSultanaR. Oxidative stress in Alzheimer's disease brain: new insights from redox proteomics. Eur J Pharmacol2006; 545: 39–50.
MartinezAPortero-OtinMPamplonaRFerrerI. Protein targets of oxidative damage in human neurodegenerative diseases with abnormal protein aggregates. Brain Pathol2010; 20: 281–97.
25.
SeehaferSSPearceDA. You say lipofuscin, we say ceroid: defining autofluorescent storage material. Neurobiol Aging2006; 27: 576–88.
26.
MecocciPPolidoriMC. Antioxidant clinical trails in mild cognitive impairment and Alzheimer's disease. Biochim Biophys Acta2012; 1822: 631–8.
27.
UttaraBSinghAVZamboniPMahajanRT. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol2009; 7: 65–74.
28.
PalaciosHHYendluriBBParvathaneniKShadlinskiVBObrenovichMELeszekJGokhmanDGasiorowskiKBraginVAlievG. Mitochondrion-specific anti-oxidants as drug treatments for Alzheimer disease. CNS Neurol Disord Drug Targets2011; 10: 149–62.
29.
Gomez-PinillaF. Brain foods: the effects of nutrients on brain function. Nat Rev2008; 9: 568–78.
30.
RiedererBM. Oxidation proteomics: the role of thiol modifications. Curr Proteomics2009; 6: 51–62.
31.
DikshitPGoswamiAMishraANukinaNJanaNR. Curcumin enhances the polyglutamine-expanded truncated N-terminal huntingtin-induced cell death by promoting proteasomal malfunction. Biochem Biophys Res Comm2006; 342: 1323–8.
32.
TaiH-CSchumanEM. Ubiquitin, the proteasome and protein degradation in neuronal function and dysfunction. Nat Rev Neurosci2008; 9: 826–38.
33.
LehmanNL. The ubiquitin proteasome system in neuropathology. Acta Neuropathol2009; 118: 329–47.
34.
OlzmannJAChinLS. Aggresome formation and neurodegenerative diseases: therapeutic implications. Curr Med Chem2008; 15: 47–60.
35.
KosikKSShimuraH. Phosphorylated tau and the neurodegenerative foldopathies. Biochem Biophys Acta2005; 1739: 298–310.
36.
SaharaNMurayamaMMizorokiTUrushitaniMImaiYTakahashiRMurataSTanakaKTakashimaA. In vivo evidence of CHIP up-regulation attenuating tau aggregation. J Neurochem2005; 94: 1254–63.
37.
CastellaniRJNunomuraALeeH-GPerryGSmithMA. Phosphorylated tau: toxic, protective, or non of the above. J Alz Dis2008; 14: 377–83.
38.
KabashiEValdmanisPNDionPRouleauGA. Oxidized/misfolded superoxide dismutase-1: the cause of all amyotrophic lateral sclerosis?Ann Neurol2007; 62: 553–9.
39.
MuñozPHuenchugualaSParisISegura-AguilarJ. Dopamine oxidation and autophagy. Parkinsons Dis2012; 2012: 1–13.
40.
TaiH-CSerrano-PozoAHashimotoTFroschMPSpires-JonesTLHymanBT. The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am J Pathol2012; 181: 1426–35.
41.
CeniniGDowlingALBeckettTLBaroneEMancusoCMurphyMPLeVineHLottITSchmittFAButterfieldDAHeadE. Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome. Biochim Biophys Acta2012; 1822: 130–8.
42.
AnsariMAScheffSW. Oxidative stress in the progression of Alzheimer disease in the frontal cortex. J Neuropathol Exp Neurol2010; 69: 155–67.
43.
SetsuieRWadaA. The functions of UCH-L1 and its relation to neurodegenerative diseases. Neurochem Int2007; 51: 105–11.
44.
GongBCaoZVitoloOVLiuSStaniszewskiAMoolmanDZhangHShelanskiMArancioO. Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory. Cell2006; 126: 775–88.
45.
ChoiJLeveyAIWeintraubSTReesHDGearingMChinLSLiL. Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinsons's disease and Alzheimer's disease. J Biol Chem2004; 279: 13256–64.
46.
de VrijFMFischerDFvan LeeuwenFWHolEM. Protein quality control in Alzheimer's disease by the ubiquitin proteasome system. Progr Neurobiol2004; 74: 249–70.
47.
GaoXHuH. Quality control of the proteins associated with neurodegenerative diseases. Acta Biochim Biophys Sin2008; 40: 612–18.
48.
YenSS. Proteasome degradation of brain cytosolic tau in Alzheimer's disease. Int J Clin Exp Pathol2011; 4: 385–402.
49.
KeckSNitschRGruneTUllrichO. Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease. J Neurochem2003; 85: 115–22.
50.
HaassCMandelkowE. Fyn-tau-amyloid: a toxic triad. Cell2010; 142: 356–8.
51.
ElHajj Z, Riederer IM, Leuba G, Vernay A, Riederer BM. Protein ubiquitination in different regions of an Alzheimer brain. Abstract No. 68 2011, USGEB Zürich:35.
52.
SinghRPSharadSKapurS. Free radicals and oxidative stress in neurodegenerative diseases: relevance of dietary antioxidants. J Ind Acad Clin Med2004; 5: 218–25.
53.
CowanCMRaymondLA. Selective neuronal degeneration in Huntington's disease. Curr Top Dev Biol2006; 75: 25–71.
54.
DelobelPLeroyOHamdaneMSamboAVDelacourteABuéeL. Proteasome inhibition and tau proteolysis: an unexpected regulation. FEBS Lett2005; 579: 1–5.
55.
NavarreteLPPérezPMoralesIMaccioniRB. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies. Curr Alz Res2011; 8: 678–85.
56.
CristalliDOArnalNMarraFAAlanizMJTMarraCA. Peripheral markers in neurodegegenrative patients and their first-degree relatives. J Neurol Sci2012; 314: 48–56.
57.
Di DomenicoFCocciaRButterfieldDAPerluigiM. Circulating biomarkers of protein oxidation for Alzheimer disease: expectations within limits. Biochim Biophys Acta2011; 1814: 1785–95.
58.
JamesSAVolitakisIAdlardPA. Elevated labile Cu is associated with oxidative pathology in Alzheimer disease. Free Rad Biol Med2012; 52: 298–302.
59.
YaoJRettbergJRKlosinskiLPCadenasEBrintonRD. Shift in brain metabolism in late onset Alzheimers's disease: implications for biomarkers and therapeutic interventions. Mol Aspects Med2011; 32: 247–57.
60.
WongHEKwonI. Xanthene food dye, as a modulator of Alzheimer's disease amyloid-beta peptide aggregartion and the associated impaired neuronal cell function. Plos ONE2011; 6: e25752–e25752.
61.
PocernichCBButterfieldDA. Elevation of glutathione as a therapeutic strategy in Alzheimer's disease. Biochim Biophys Acta2012; 1822: 625–30.
62.
FarrSAPoonHFDogrukol-AkDDrakeJBanksWAEyermanEButterfieldDAMorleyJE. The antioxidant -lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J Neurochem2003; 84: 1173–83.
63.
das Neves DuarteJMKulakAGholam-RazaeeMMCuenodMGruetterRDoKQ. N-acetylcysteine normalizes neurochemical changes in the glutathione-deficient schizophrenia mouse model during development. Biol Psy2012; 71: 1006–14.
64.
RiedererIMMoreno HerreroRLeubaGRiedererBM. Serial protein labeling with infrared maleimide dyes to identify cysteine modifications. J Proteomics2008; 71: 222–30.
